Baxter
This article was originally published in The Gray Sheet
Executive Summary
Issuing $200 mil. of notes, bearing an annual interest rate of 7.25%, to repay existing debt. The notes are due Feb. 15, 2008 and are priced at 99.728%. Underwriting the issue is First Boston Corporation; Goldman, Sachs; Merrill Lynch; and J. P. Morgan Securities. Baxter initiated two separate offerings of $150 mil. in notes in the fall of 1992 ("The Gray Sheet" Nov. 9, p. 20).
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.